Glutamine (Endari) Shortage Update: What Patients Need to Know in 2026

If you've been struggling to fill your Glutamine (Endari) prescription, you may be wondering: is there an official shortage? The short answer is no — but the access problem is real, and it affects thousands of patients with sickle cell disease across the United States.

Here's everything you need to know about Glutamine availability in 2026, why patients are struggling to get it, and what you can do.

Is Glutamine (Endari) on the FDA Shortage List in 2026?

As of 2026, Glutamine (Endari and its generic L-glutamine oral powder) is NOT listed on the FDA's official drug shortage database. The FDA shortage list covers medications experiencing supply disruptions at the manufacturing or distribution level.

However, being absent from the FDA shortage list doesn't mean every patient can get their prescription filled easily. Glutamine has a different kind of access problem — one rooted in its specialty pharmacy distribution model, high cost, and insurance requirements.

What's the Real Access Problem?

Real-world data paints a stark picture of how hard Glutamine is to access in practice. A study conducted at Montefiore Medical Center found that after 10 months of follow-up among 101 patients prescribed L-glutamine:

Only 21% were actively taking the medication

43% had discontinued treatment

33% never filled the prescription at all

These numbers reflect a systemic access problem, not a supply problem. The barriers are primarily insurance-related (prior authorization, step therapy, Tier 5 placement) and structural (specialty-only dispensing, high retail cost).

Timeline: Key Events in Glutamine Availability

July 2017: FDA approves Endari (brand-name L-glutamine oral powder) — the first new SCD treatment in almost 20 years

January 2019: Emmaus launches copay assistance program for commercially insured patients

December 2020: Emmaus launches the Endari Support Program for uninsured and underinsured patients

September 2024: Voxelotor (Oxbryta) — another SCD drug — is withdrawn from market, increasing demand for Glutamine and hydroxyurea

July 2024: First FDA-approved generic L-glutamine oral powder launched by ANI Pharmaceuticals — potentially improving long-term access

2026: No active FDA shortage; access challenges persist due to specialty pharmacy requirements and insurance barriers

How Does the Withdrawal of Voxelotor Affect Glutamine Access?

When Pfizer pulled voxelotor (Oxbryta) from the market in September 2024, thousands of SCD patients were suddenly without one of their medications. Many of those patients — and their doctors — turned to the remaining FDA-approved options: hydroxyurea, crizanlizumab, and Glutamine.

This increased demand for Glutamine — potentially stressing specialty pharmacy supply chains and insurance prior authorization systems — is an important factor for 2026. If you're newly starting Glutamine after stopping voxelotor, give yourself extra time for insurance approval and pharmacy search.

What to Do If You Can't Get Your Glutamine Prescription Filled

Whether it's an insurance issue, a pharmacy availability problem, or a cost barrier, here are the most effective steps you can take today:

Contact your SCD care team immediately. Don't wait until you run out. Alert your hematologist or nurse navigator as soon as you anticipate a problem — they have the most direct path to getting your prescription resolved.

Use medfinder to search pharmacies near you. medfinder calls pharmacies in your area to find which ones have Glutamine in stock and can fill your prescription. Results are sent by text.

Enroll in the Endari Support Program. If cost is the issue, call 1-855-723-5646. Commercially insured patients may pay as little as $10/month; uninsured patients may qualify for minimal or no-cost medication.

Ask your doctor to pursue an insurance appeal. If your initial prior authorization was denied, your prescriber can submit a peer-to-peer review or formal appeal. Most denials can be overturned with proper documentation.

Will Glutamine Ever Be Easier to Get?

The launch of the first FDA-approved generic L-glutamine oral powder in July 2024 is a positive step. Over time, as more generic manufacturers enter the market, competition could reduce prices and improve availability at more pharmacy types. However, the specialty pharmacy requirement may remain a structural barrier unless insurance and regulatory policies change.

See also: Why is Glutamine so hard to find? | Alternatives to Glutamine for sickle cell disease